Is Compass Pathways Stock a Buy?
This small-cap biotech may very well revolutionize how we treat depression.
COMPASS Pathways plc
CMPS
CMPS
$45.33
$2.83
6.7%
Price as of January 19, 2021, 9:00 p.m. EST
View Interactive CMPS Charts
COMPASS Pathways plc
Interactive Chart
News & Analysis: COMPASS Pathways plc
Is Compass Pathways a Good Stock to Buy Now?
The company's fresh look at psychedelic drugs is attracting lots of attention.
Missed Out on Marijuana Stocks? Psychedelic Stocks Could Be the Next Big Thing
The market is in its early stage, and the players in the space could have a lot of room to run.
Is Compass Pathways Stock a Buy?
Oregon just decriminalized the use of the psychedelic compound psilocybin. Could Compass Pathways, which is testing a synthetic form of the drug as a mental health therapy, be on the cusp of something big?
COMPASS Pathways plc (CMPS) Q3 2020 Earnings Call Transcript
CMPS earnings call for the period ending September 30, 2020.
This 1 Stock Is a Definite Winner in the Election
Oregon became the first state in the nation to legalize the therapeutic use of psychedelic mushrooms, raising awareness for this biotech's trailblazing treatment.
This Biotech Stock Was a Winner Last Night
Voters in Oregon approved a ballot measure that legalizes a treatment this newly public company has in clinical trials.
Why COMPASS Pathways Mushroomed Almost 20% Today
The trailblazing company studying the use of the psychedelic drug found in magic mushrooms to treat mental health is starting to make waves.
Why Compass Pathways Stock Is Soaring Today
A short-seller likes the recent IPO stock.
